Introduction & Objective: Diabetic peripheral neuropathy (DPN) is often diagnosed late. Point-of-care-devices (POCDs, ‘DPN-Check’ a handheld device which measures sural-nerve conduction-velocity/amplitude and SUDOSCAN a test of sudomotor-function) are objective, quick tests that when combined; accurately diagnose DPN. However, the ability of POCDs to predict incident DPN is unknown, and was examined in this prospective study.

Methods: 229 consecutive participants with diabetes who attended one-stop microvascular screening service were re-called for follow-up evaluation at 7 years. Baseline assessments were repeated including: clinical and neurophysiological assessments of DPN [Toronto Clinical Neuropathy Score (TCNS),10g monofilament (10g-MFT), POCDs and nerve conduction studies (NCS). Risk of developing incident DPN was assessed using the odds-ratio for the diagnosis of DPN using clinical (TCNS, 10gMFT) and NCS.

Results: 90 participants have completed follow up visits. Patients attending follow up were significantly younger [57.8(11.9)vs62.5(14.2)years; (p<0.001(95%CI 4.1:11.4)] than those who did not (n=139), and had lower number of co-morbidities [3.0vs5.5; P<0.001] and Q-risk (20.3(13.1)vs29.3(13.5); p<0.001). Thirty-four (37.8%) patients had incident 10g MFT abnormality at follow-up. Patients with abnormal POCDs had a OR 7.1(p<0.001;95%CI:2.3:22.8) times greater risk of 10g-MFT abnormality compared to those with normal POCDs at baseline. Similar increased risk of incident DPN were found when DPN was diagnosed using TCNS [OR 4.0(95%CI1.0:15.2, p=0.03)] and NCS [OR 11.9(95%CI:1.5:96.0, p=0.005)].

Conclusions: We have demonstrated significantly increased risk of incident clinical DPN in patients with abnormal baseline POCDs (microalbuminuria equivalent). These findings support the use of POCDs as a screening tool for early DPN diagnosis, when cardio-metabolic control may halt the progressive neuropathic process.

Disclosure

M. Goonoo: None. D. Selvarajah: Research Support; Abbott. Speaker's Bureau; Grunenthal. Research Support; Impeto medical. G.P. Sloan: Other Relationship; Procter & Gamble, Lilly Diabetes. S. Tesfaye: Advisory Panel; Angelini Pharma, AstraZeneca, Bayer Inc., Worwag Pharma, Nevro Corp. Other Relationship; GlaxoSmithKline plc, Novo Nordisk Foundation. Speaker's Bureau; Procter & Gamble, Viatris Inc. Research Support; Withings, Viatris Inc., Procter & Gamble.

Funding

Proctor & Gamble Health (STH SPONSOR ID STH22196)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.